Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

GRCE

Grace Therapeutics Inc

Dec 30 • 11:35AM ET

3.64

Dollar change -0.07
Percentage change -1.89	%

Healthcare • Biotechnology • USA • NASD

Held by: VTI

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.08	Insider Own	38.40%	Shs Outstand	10.14M	Perf Week	-4.71%
Market Cap	37.01M	Forward P/E	-	EPS next Y	-0.86	Insider Trans	0.00%	Shs Float	6.25M	Perf Month	8.01%
Income	-11.61M	PEG	-	EPS next Q	-0.32	Inst Own	20.90%	Short Float	1.30%	Perf Quarter	21.33%
Sales	0.00M	P/S	-	EPS this Y	9.63%	Inst Trans	34.34%	Short Ratio	1.69	Perf Half Y	24.66%
Book/sh	5.54	P/B	0.66	EPS next Y	29.51%	ROA	-16.17%	Short Interest	0.08M	Perf Year	25.09%
Cash/sh	1.49	P/C	2.44	EPS next 5Y	-	ROE	-18.89%	52W Range	1.98 - 4.97	Perf YTD	25.95%
Dividend Est.	-	P/FCF	-	EPS past 5Y	47.80%	ROI	-20.68%	52W High	-26.69%	Beta	1.46
Dividend TTM	-	Quick Ratio	6.01	Sales past 5Y	-20.00%	Gross Margin	-	52W Low	83.84%	ATR (14)	0.37
Dividend Ex-Date	-	Current Ratio	6.01	EPS Y/Y TTM	79.99%	Oper. Margin	-	RSI (14)	49.10	Volatility	11.26% 11.02%
Employees	4	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	10.83
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	31.17%	Payout	-	Rel Volume	2.13	Prev Close	3.71
Sales Surprise	-	EPS Surprise	18.92%	Sales Q/Q	-	Earnings	Nov 13 BMO	Avg Volume	48.07K	Price	3.64
SMA20	-5.33%	SMA50	4.87%	SMA200	19.30%	Trades		Volume	36,562	Change	-1.89%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-01-20	Downgrade	Oppenheimer	Outperform → Perform
Jul-06-20	Upgrade	B. Riley FBR	Neutral → Buy	$2
Jan-13-20	Downgrade	B. Riley FBR	Buy → Neutral
Aug-29-19	Initiated	B. Riley FBR	Buy	$7.75
Jul-18-19	Initiated	Oppenheimer	Outperform	$7
Jun-26-19	Initiated	H.C. Wainwright	Buy	$6

Dec-04-24 08:00AM	Grace Therapeutics to Exhibit at the American Society of Health-System Pharmacists Conference (GlobeNewswire) +20.00%
Nov-13-24 08:00AM	Grace Therapeutics Announces Second Fiscal Quarter 2025 Financial Results, Provides Business Update (GlobeNewswire)
Oct-30-24 08:00AM	Grace Therapeutics to Host Virtual KOL Event on GTx-104 in aneurysmal Subarachnoid Hemorrhage on November 20, 2024 (GlobeNewswire)
Oct-25-24 08:00AM	Acasti Announces Corporate Name Change to Grace Therapeutics, Inc. (GlobeNewswire)
Sep-25-24 07:30AM	Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104 (GlobeNewswire) +19.53%
08:35AM	Loading…
Sep-20-24 08:35AM	Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing (GlobeNewswire)
Sep-16-24 12:07PM	Life Sciences Virtual Investor Forum Agenda Announced for September 19th (GlobeNewswire) +12.43%
Sep-12-24 08:00AM	Acasti to Present at the Life Sciences Investor Forum (GlobeNewswire) -8.38%
Sep-05-24 10:35AM	Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-09-24 02:52PM	ACST Stock Earnings: Acasti Pharma Beats EPS for Q1 2025 (InvestorPlace)
08:00AM	Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update (GlobeNewswire)
Jul-10-24 09:40AM	Is Acasti Pharma (ACST) Outperforming Other Medical Stocks This Year? (Zacks)
Jun-27-24 04:05PM	Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial (GlobeNewswire)
Jun-21-24 01:53PM	ACST Stock Earnings: Acasti Pharma Beats EPS for Q4 2024 (InvestorPlace)
08:00AM	Acasti Announces Year-End 2024 Financial Results, Provides Business Update (GlobeNewswire)
12:31PM	Loading…
Jun-18-24 12:31PM	Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024 (InvestorPlace)
May-28-24 04:05PM	Acasti Pharma to Attend BIO International Convention 2024 (GlobeNewswire)
May-23-24 06:45AM	The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom (InvestorPlace)
Mar-24-24 03:54PM	12 Best Biotech Penny Stocks to Invest In (Insider Monkey)
Feb-12-24 08:00AM	Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights (GlobeNewswire) +6.53%
07:57AM	Acasti: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
Feb-01-24 08:00AM	Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial (GlobeNewswire)
Dec-13-23 08:00AM	Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024 (GlobeNewswire)
Nov-13-23 08:20AM	Acasti: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	Acasti Announces Second Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Oct-23-23 08:00AM	Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial (GlobeNewswire)
Oct-04-23 08:00AM	Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH) (GlobeNewswire)
Sep-26-23 08:00AM	Acasti Announces $7.5 Million Private Placement Equity Financing (GlobeNewswire) +35.39%
Sep-06-23 08:00AM	Acasti to Participate in the H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-23-23 03:49AM	TEVA to Pay $225 Million to Settle Price-Fixing Charges (Revised) (Zacks)
09:19AM	Loading…
Aug-22-23 09:19AM	TEVA to Pay $250 Million to Settle Price-Fixing Charges (Zacks)
Aug-11-23 07:10AM	Acasti: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Acasti Announces First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Aug-09-23 04:05PM	Acasti to Present GTX-104 Pharmacokinetic Comparison Data at Neurocritical Care Annual Meeting (GlobeNewswire)
Jul-28-23 08:02AM	Dr. Reddy's (RDY) Q1 Earnings and Revenues Beat Estimates (Zacks)
Jul-10-23 09:00AM	Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients (PR Newswire) -9.55%
Jul-07-23 08:00AM	Acasti Pharma Announces 1-for-6 Reverse Stock Split (PR Newswire) -12.52%
Jul-05-23 09:00AM	Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023 (PR Newswire) +18.77%
Jun-23-23 07:00AM	Acasti Pharma Reports Fiscal Year 2023 Operational Results (PR Newswire)
Jun-22-23 09:00AM	Acasti Announces Appointment of New Scientific Advisory Board Members (PR Newswire)
May-17-23 09:00AM	Acasti to Participate in the Lytham Partners Spring 2023 Investor Conference (PR Newswire)
May-10-23 07:41AM	We're Hopeful That Acasti Pharma (NASDAQ:ACST) Will Use Its Cash Wisely (Simply Wall St.)
May-08-23 07:00AM	Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025 (PR Newswire)
Apr-04-23 08:01AM	Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND (PR Newswire)
08:00AM	Acasti Announces Appointment of Prashant Kohli as CEO (PR Newswire)
Mar-30-23 08:30AM	Acasti Pharma Inc. Announces the Resignation of a Director (PR Newswire)
06:57AM	When Will Acasti Pharma Inc. (NASDAQ:ACST) Turn A Profit? (Simply Wall St.)
Mar-13-23 08:00AM	Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange (PR Newswire)
Mar-08-23 09:00AM	Acasti Pharma to Participate in Oppenheimer 33rd Annual Healthcare Conference (PR Newswire)
Mar-04-23 08:28AM	We're Hopeful That Acasti Pharma (CVE:ACST) Will Use Its Cash Wisely (Simply Wall St.)
Feb-28-23 01:00PM	Acasti Pharma Recognizes Rare Disease Day (PR Newswire)
09:40AM	Has Acasti Pharma (ACST) Outpaced Other Medical Stocks This Year? (Zacks)
Feb-15-23 04:02PM	Acasti Pharma Inc. (NASDAQ:ACST) Q3 2023 Earnings Call Transcript (Insider Monkey)
Feb-14-23 07:00AM	Acasti Pharma Reports Third Quarter 2023 Operational Results (GlobeNewswire)
Feb-07-23 09:00AM	Acasti Pharma to Report Third Quarter 2023 Financial Results on Tuesday, February 14, 2023 (PR Newswire)
Jan-25-23 09:00AM	Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule (GlobeNewswire)
Jan-24-23 04:15PM	Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31 (GlobeNewswire)
Jan-17-23 10:00AM	Sidoti's January Micro-Cap Conference (ACCESSWIRE) +5.63%
08:45AM	Acasti Pharma Discusses Positive Clinical Study Results for GTX-101 and GTX-102 and Upcoming Phase 3 Study for GTX-104 with The Stock Day Podcast (Newsfile)
Jan-13-23 09:00AM	Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18 (GlobeNewswire)
Jan-05-23 09:00AM	Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures (GlobeNewswire) +18.32%
Dec-29-22 06:02AM	Acasti Pharma Inc. (NASDAQ:ACST) Q2 2023 Earnings Call Transcript (Insider Monkey)
Dec-28-22 08:00AM	Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Companys Drug Candidate for the Treatment of Ataxia Telangiectasia (GlobeNewswire) +11.09%
Dec-22-22 08:00AM	Acasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Companys Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN) (GlobeNewswire) +11.99%
Nov-14-22 07:00AM	Acasti Pharma Reports Second Quarter 2023 Operational Results (GlobeNewswire)
Nov-09-22 04:15PM	Acasti Pharma to Present at Q4 Investor Summit (GlobeNewswire)
Nov-07-22 04:15PM	Acasti Pharma to Report Second Quarter 2023 Financial Results on Monday, November 14, 2022 (GlobeNewswire) -6.01%
Sep-30-22 09:00AM	Acasti Announces Court Dismissal of Stockholder Litigation (GlobeNewswire)
Sep-29-22 09:00AM	Acasti Announces Voting Results from 2022 Annual and Special Meeting of Shareholders (GlobeNewswire)
Sep-21-22 08:45AM	Acasti Pharma Inc. Discusses Clinical Progress of Lead Assets and 2022 Catalysts with The Stock Day Podcast (Newsfile)
Sep-14-22 04:15PM	Acasti Pharma to Participate in the Lytham Partners Fall 2022 Investor Conference (GlobeNewswire)
Sep-13-22 08:00AM	Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, the Companys Drug Candidate for the Treatment of Ataxia Telangiectasia (GlobeNewswire)
Sep-12-22 09:00AM	Acasti Pharma to Participate at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-11-22 01:00PM	Edited Transcript of ACST.V earnings conference call or presentation 11-Aug-22 5:00pm GMT (Thomson Reuters StreetEvents)
07:00AM	Acasti Pharma Reports First Quarter 2023 Operational Results (GlobeNewswire)
Aug-02-22 04:15PM	Acasti Pharma to Report First Quarter 2023 Financial Results on Thursday, August 11, 2022 (GlobeNewswire)
Jul-27-22 08:00AM	Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-101, the Companys Drug Candidate for the Treatment of Postherpetic Neuralgia (GlobeNewswire)
Jul-07-22 08:55AM	Acasti Pharma Inc. Discusses Year-End Results and Clinical Development Progress with The Stock Day Podcast (Newsfile)
Jun-22-22 06:10PM	Acasti Pharma Announces Annual Grants of Performance Stock Options (GlobeNewswire)
Jun-21-22 08:00AM	Acasti Pharma Reports Fiscal Year 2022 Operational Results (GlobeNewswire)
Jun-16-22 04:15PM	Acasti Pharma Schedules Fiscal Year 2022 Business Update Conference Call (GlobeNewswire) -5.26%
Jun-14-22 08:00AM	Acasti Pharma Announces the Issuance of Additional Patents for GTX-104 and GTX-101 (GlobeNewswire)
May-23-22 04:15PM	Acasti Pharma Inc. Retains Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program (PR Newswire)
May-18-22 11:20AM	Acasti Pharma's IV Hemorrhage Drug Candidate At Par With Oral Nimodipine (Benzinga)
07:30AM	Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, With Intravenous GTX-104 Meeting All Endpoints (GlobeNewswire)
May-16-22 01:30PM	Update: Acasti Pharma CEO to Present at Microcap Rodeos Spring into Action Best Ideas Virtual Conference on May 18th (ACCESSWIRE)
01:20PM	36 of the Best Ideas Companies to Present at the Spring into Action - Best Ideas Investor Conference on May 16th - 20th, 2022 (ACCESSWIRE)
May-12-22 08:00AM	Acasti Pharma CEO to Present at Microcap Rodeo's Spring into Action Best Ideas Virtual Conference on May 16th (ACCESSWIRE)
May-06-22 09:02AM	10 Biotech Penny Stocks Redditors Love (Insider Monkey)
Apr-25-22 08:30AM	Acasti Pharma to Present at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference on April 28th (GlobeNewswire)
Mar-25-22 07:30AM	Acasti Pharma Appoints Healthcare Industry Leader Michael L. Derby to its Board of Directors (GlobeNewswire)
Mar-22-22 07:30AM	Acasti Pharma Announces Patents for GTX-104 in Europe, GTX-102 in the U.S. and GTX-101 in Japan (GlobeNewswire)
Mar-09-22 08:30AM	Acasti Pharma CEO to Present at the 32nd Annual Oppenheimer Healthcare Conference on March 16th (GlobeNewswire)
Feb-28-22 08:30AM	Acasti Pharma Celebrates Rare Disease Day (GlobeNewswire)
Feb-23-22 09:50AM	New Strong Sell Stocks for February 23rd (Zacks)
Feb-22-22 09:09AM	Acasti Pharma Inc. CEO, Jan D'Alvise, Is Featured on The Stock Day Podcast (Newsfile) -6.78%
Feb-14-22 07:00AM	Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2022 (GlobeNewswire) +7.02%
Feb-07-22 08:30AM	Acasti Pharma Schedules Third Quarter Fiscal 2022 Business Update Conference Call (GlobeNewswire)
Jan-03-22 08:30AM	Acasti Pharma to Present at the H.C. Wainwright BioConnect 2022 Conference (GlobeNewswire) +9.52%
Dec-23-21 10:49AM	BLITF Stock: 7 Thing to Know About Mobile Gaming Play i3 Interactive as Shares Rocket Today (InvestorPlace) -17.16%

Grace Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland and Pierre Lemieux on February 1, 2002, and is headquartered in Princeton, NJ.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GRCE

Grace Therapeutics Inc

Upgrade your FINVIZ experience